Ocular Therapeutix (OCUL) Cash & Equivalents (2013 - 2026)
Ocular Therapeutix's quarterly Cash & Equivalents came in at $666.7 million in Q1 2026, up 90.66% year-on-year from $349.7 million in Q1 2025, and down 9.55% quarter-over-quarter from $737.1 million in Q4 2025.
Ocular Therapeutix has reported Cash & Equivalents for 14 years, with the latest figure at $666.7 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Equivalents rose 90.66% year-over-year to $666.7 million; the trailing twelve-month figure through Mar 2026 stood at $666.7 million (up 90.66% YoY), and the FY2025 full-year result was $737.1 million, up 87.98% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $666.7 million, down from $737.1 million in the prior quarter.
- The five-year high for Cash & Equivalents was $737.1 million in Q4 2025, with the low at $66.6 million in Q2 2023.
- Average Cash & Equivalents over 5 years is $306.3 million, with a median of $344.8 million recorded in 2025.
- Year-over-year, Cash & Equivalents tumbled 50.49% in 2023 and surged 590.16% in 2024.
- Tracing OCUL's Cash & Equivalents over 5 years: stood at $102.3 million in 2022, then jumped by 91.4% to $195.8 million in 2023, then surged by 100.25% to $392.1 million in 2024, then soared by 87.98% to $737.1 million in 2025, then fell by 9.55% to $666.7 million in 2026.
- The last three Cash & Equivalents figures came in at $666.7 million (Q1 2026), $737.1 million (Q4 2025), and $344.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | 666.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 666.70 Mn |
| Dec 31, 2025 | 737.06 Mn |
| Sep 30, 2025 | 344.77 Mn |
| Jun 30, 2025 | 391.13 Mn |
| Mar 31, 2025 | 349.68 Mn |
| Dec 31, 2024 | 392.10 Mn |
| Sep 30, 2024 | 427.22 Mn |
| Jun 30, 2024 | 459.69 Mn |
| Mar 31, 2024 | 482.89 Mn |
| Dec 31, 2023 | 195.81 Mn |
| Sep 30, 2023 | 110.55 Mn |
| Jun 30, 2023 | 66.61 Mn |
| Mar 31, 2023 | 79.03 Mn |
| Dec 31, 2022 | 102.30 Mn |
| Sep 30, 2022 | 120.95 Mn |
| Jun 30, 2022 | 134.54 Mn |
| Mar 31, 2022 | 145.42 Mn |
| Dec 31, 2021 | 164.16 Mn |
| Sep 30, 2021 | 179.28 Mn |
| Jun 30, 2021 | 191.86 Mn |
| Mar 31, 2021 | 209.38 Mn |
| Dec 31, 2020 | 228.06 Mn |
| Sep 30, 2020 | 70.64 Mn |
| Jun 30, 2020 | 84.29 Mn |
| Mar 31, 2020 | 48.15 Mn |
| Dec 31, 2019 | 54.44 Mn |
| Sep 30, 2019 | 65.41 Mn |
| Jun 30, 2019 | 61.77 Mn |
| Mar 31, 2019 | 76.25 Mn |
| Dec 31, 2018 | 54.06 Mn |
| Sep 30, 2018 | 56.86 Mn |
| Jun 30, 2018 | 56.83 Mn |
| Mar 31, 2018 | 62.91 Mn |
| Dec 31, 2017 | 41.54 Mn |
| Sep 30, 2017 | 51.17 Mn |
| Jun 30, 2017 | 63.05 Mn |
| Mar 31, 2017 | 54.68 Mn |
| Dec 31, 2016 | 32.94 Mn |
| Sep 30, 2016 | 52.23 Mn |
| Jun 30, 2016 | 48.17 Mn |
| Mar 31, 2016 | 46.21 Mn |
| Dec 31, 2015 | 30.78 Mn |
| Sep 30, 2015 | 41.20 Mn |
| Jun 30, 2015 | 78.69 Mn |
| Mar 31, 2015 | 12.52 Mn |
| Dec 31, 2014 | 37.39 Mn |
| Sep 30, 2014 | 80.89 Mn |
| Jun 30, 2014 | 19.94 Mn |
| Mar 31, 2014 | 12.75 Mn |
| Dec 31, 2013 | 17.51 Mn |
| Sep 30, 2013 | 21.62 Mn |
| Jun 30, 2013 | 25.03 Mn |